Health & Wellness

Press Releases

Atlantic Health System Announces Clinical Trial of Drug for Locally Advanced or Metastatic Pancreatic Cancer Patients

Dr. Angela Alistar

Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a Phase I clinical trial of CPI-613 in combination with chemotherapeutic agents, gemcitabine and nab-paclitaxel, for patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in collaboration with Atlantic Health System. CPI-613 is a first-in-class drug with a unique mode of action and is Rafael’s lead altered energy metabolism directed (AEMD) drug candidate. The drug is designed to disrupt the altered energy-production pathways in cancer cells by targeting their mitochondrial metabolism.

The primary aim of the study is to establish the maximum tolerated dose of CPI-613 when given in combination with gemcitabine/nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.

Secondary aims include:

Sign Up for E-News

(1) To describe the safety profile for the gemcitabine/nab-paclitaxel/CPI-613 combination.
(2) To determine the clinical activity of gemcitabine/nab-paclitaxel/CPI-613 in metastatic pancreatic cancer as measured by tumor response rate (RR) by RECIST criteria, progression-free survival (PFS), and overall survival (OS).

Encouraging results observed in earlier trials, including Phase I data from a trial led by Angela Alistar, MD that was recently published in The Lancet Oncology, demonstrated the preliminary efficacy of CPI-613 in combination with modified FOLFIRINOX (a multidrug treatment for advanced pancreatic cancer) in patients with metastatic pancreatic cancer. These results support further evaluation of CPI-613 in this indication.[1] The safety profile of CPI-613 in earlier trials, which shows the drug to be well tolerated, provides further support for evaluation of CPI-613 in combination with other drugs to maximize benefit.

In 2013, the MPACT study, a multinational, phase III clinical trial comparing gemcitabine/nab-paclitaxel to gemcitabine alone, demonstrated an improved median survival of 8.5 months as compared with 6.7 months for gemcitabine monotherapy (p=0.000015). While some clinical benefit was shown, these outcomes also highlight the need for new combination strategies to improve upon the outcomes seen with gemcitabine/nab-paclitaxel in the treatment of metastatic pancreatic cancer.

Dr. Alistar, medical director of GI Medical Oncology at the Carol G. Simon Cancer Center of Morristown Medical Center, Atlantic Health System, and the Principal Investigator for this trial, remarked, “Strategies to enhance our current standard of care options are sorely needed in pancreatic cancer. Due to the low toxicity profile of CPI -613 as a single agent, I anticipate good tolerance in combination with the gemcitabine/nab-paclitaxel regimen. I am excited to be able to offer this novel option to our patients with pancreatic cancer. Targeting metabolism in pancreatic cancer has a strong scientific rationale.”

Sanjeev Luther, Rafael Pharmaceuticals’ Chief Executive Officer, commented, “Our company’s motto of “One Patient at a Time” is especially relevant in this situation. Patients with a low tolerance for toxicity may not be eligible for the FOLFIRINOX combo. We believe that the gemcitabine/nab-paclitaxel regimen has the potential to be a potent treatment with less toxicity. It is especially meaningful for us to announce the initiation of this study on World Pancreatic Cancer Day.”

About Atlantic Health System

Atlantic Health System, headquartered in Morristown, N.J., is an integrated health care delivery system powered by a workforce of 16,000 team members dedicated to building healthier communities. The system is comprised of 350 sites of care, including six hospitals: Morristown Medical Center, Overlook Medical Center, Newton Medical Center, Chilton Medical Center, Hackettstown Medical Center and Goryeb Children’s Hospital. Atlantic Health System also supports communities through Atlantic Medical Group, Atlantic Rehabilitation, Atlantic Home Care and Hospice, and its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System sponsors the Atlantic Accountable Care Organization, one of the larger ACOs in the nation, and Optimus Healthcare Partners. 

 

About Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Reference

[1] Alistar A, Morris BB, Desnoyer R, et al. (2017). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. The Lancet Oncology. doi: 10.1016/S1470-2045(17)30314-5.

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Summit

Upcoming Events

Carousel_image_cd3383449e34ac696de0_58eba447e8216c280815_storytime

Wed, December 13, 10:00 AM

Summit Free Public Library, Summit

Storytime Stars

Arts & Entertainment Community Calendar Education

Carousel_image_775341755924245083fc_eee41d23cf289e845d15_cc516b3eb1f79e6a0105_vigil-750x500

Wed, December 13, 6:00 PM

Congregation Ohr Shalom, Summit

Candlelight Vigil Against Gun Violence

Law & Justice Religions And Spirituality

Carousel_image_af17e1b51c0aa19a89a6_6bdd4bb1a56c3a2562a5_storytime

Thu, December 14, 10:00 AM

Summit Free Public Library, Summit

Spanish Storytime

Arts & Entertainment Community Calendar Education

Summit Fire Department Blotter

October 18, 2017 at 3:22 pm FD units dispatched to a Morris Avenue business for an alarm activation.  On arrival investigation found that a malfunctioning temporary light fixture had arced and activated a detector on the first floor.  FD removed the fixture and reset the alarm

October 20, 2017 at 22:42 FD dispatched to Summit Train Station for a report of a trash can smoking. On ...

Summit Police Blotter

December 11, 2017

1/28 - At 0546 hours a report was taken for a burglary to a Beechwood Road business. The incident occurred at approximately 0440 hours where the suspect removed a cash register and ten (10) packs of Kool Cigarettes. The suspect was described as a white male, with a chin-strap beard, wearing a beanie cap, a light hooded sweatshirt, and black shoes. Total value of the stolen items was approximately ...

Dr. K. Advises 'See Your Doctor in Sickness and in Health'

December 12, 2017

About 3 years ago, around the time healthcare was saying its last goodbyes to solo practitioners, I decided to plunge into the world of private practice and one morning announced to my family, “I am starting a new primary care solo practice.”

I am an Internist of Asian Indian origin and I graduated from residency about twenty years ago. To say that my family was bewildered is an ...

Video: Point View's Petrides Says Technology Has Made Economy 'More Efficient'

Point View Wealth Management's Managing Director and Portfolio Manager, John Petrides, live on Fox Business AM discussing if Amazon and ecommerce is impacting Fed interest rate policy:

video.foxbusiness.com

For nearly 25 years, Point View Wealth Management, Inc. has been working with families in Summit and beyond, providing customized portfolio management ...

Favor Value Over Growth for 2018

Pricey growth stocks have been all the rage in 2017, running circles around cheaper value plays. We believe that one of the most powerful forces in investing, reversion to the mean, may cause value stocks to outperform in 2018.  Position your portfolio accordingly.

Understand the Difference Between Value and Growth

Growth stocks are typically more expensive than value stocks.

Ain't That Grand?

Hometown Gal Comes Back to Hilltop City, Brings a Bit of 'Southern Hospitality' to Summit's Most Hospitable Address

Maybe you can go home again, after all.

Katie Ogden is a shining example that proves that twist on an age-old adage.

After seven years in Memphis, Ogden is home in the Hilltop City and she has found a new work home as well, recently becoming the front desk manager at the Grand Summit Hotel.

And, if there's a smidgen of a 'twang' seeping into the welcomes, can I help ...

The Floor Plan

For Luxury and Durability, Make LVP Your MVP

Combine durable vinyl with the realistic look of wood in a plank format and you have a surface that offers the best of all worlds, one that is the perfect flooring solution for any room in your home.

Luxury Vinyl Plank -- or 'LVP' flooring is:

Water Resistant
Durable
Soft Underfoot
Easy Care
Budget Friendly

Unlike natural woods, LVP can be used in areas where ...

AtlantiCast: Episode 008

On this week’s AtlantiCast, you’ll learn about a groundbreaking new clinical trial in the fight against pancreatic cancer, meet an award-winning child neurologist at Goryeb Children’s Hospital and hear about the new Scoliosis and Spinal Deformity Center at Atlantic Orthopedic Institute – plus stay tuned at the end to see our debut episode of the AtlantiCast Medical ...

Investors Bank October 2017 Fed Normalization Process

The Federal Reserve has increased interest rates twice this year and could do so again in December.  But the economy is hardly booming along and inflation remains tame.  Are the central bankers crazy?  No!  They simply are trying to add some monetary policy arrows to their largely empty quiver.

The near collapse of the world financial system in 2008, forced the Fed to take ...

Don't Let 'Old Man Winter' Drive You Crazy: Follow This Handy Seasonal Car Care Checklist

As if driving during nasty, cold conditions is not enough of a challenge, having 'car trouble' in the wintertime can be about as much fun as the farcical examples used in a satellite television provider commercial that pokes fun at the cable companies... you know, like getting paper cuts on your tongue, getting your arm caught in a vending  machine, spilling hot coffee ...

The Thought that Counts

The other day I was talking to our cat . . .  

Hmmm.  It says here that dogs are smarter than cats.

What are you reading, Mad Magazine?

No seriously, this article in the Times claims that a scientific study conducted at Vanderbilt University recently discovered that dogs have twice as many neurons as cats in the analytic part of their brains.

Yeah, but they only use a ...